Polaris Group signs collaboration agreement with Nanotein Technologies, Inc.

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Polaris announces to enroll the first patient of Phase IB Clinical Trial in GBM

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Polaris Group Announces officially secured USD $100 million new funding

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Polaris Group ADI-PEG20 on the cover of AACR journals

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Polaris Group Announces Dr. Shaw Chen as New Interim CEO

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Polaris Group Announces Wayne Lin as New COO

Polaris Group Announces Wayne Lin as New COO…

Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board

Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board…

Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board

Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group), a biopharmaceutical company focused on developing novel drugs for cancer, announced that James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. have joined its Scientific Advisory Board …

Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 in Metastatic Uveal Melanomas

SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI-PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas…

Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 in Combination with Pembrolizumab for Advanced Solid Tumors

SAN DIEGO, June 04 2018 – At the American Society Clinical Oncology’s 2018 annual meeting, scientists from National Institute of Cancer Research Taiwan reported results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with pembrolizumab has activity for advanced solid tumors…